Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Completed 4

Sponsor Class

INDUSTRY 2OTHER_GOV 1OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Breast Neoplasms 2046Neoplasms 1460Carcinoma, Non-Small-Cell Lung 1364Prostatic Neoplasms 1106Multiple Myeloma 873Leukemia, Myeloid, Acute 772Colorectal Neoplasms 713Neoplasm Metastasis 704Lung Neoplasms 697Melanoma 688Lymphoma 666Leukemia 596Lymphoma, Non-Hodgkin 593Leukemia, Lymphocytic, Chronic, B-Cell 535Ovarian Neoplasms 535Pancreatic Neoplasms 500Precursor Cell Lymphoblastic Leukemia-Lymphoma 485Recurrence 474Myelodysplastic Syndromes 425Lymphoma, Follicular 418Carcinoma, Renal Cell 412Head and Neck Neoplasms 408Glioblastoma 380Lymphoma, Large B-Cell, Diffuse 379Brain Neoplasms 376Hodgkin Disease 354Carcinoma, Hepatocellular 333Squamous Cell Carcinoma of Head and Neck 326Lymphoma, Mantle-Cell 306Sarcoma 286

Interventions

Interferon alpha-2 1Everolimus 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Has results × Margins of Excision × Clear all
NCT04918381 2023-01-11

CellFX Treat & Resect Low-Risk BCC Feasibility Study

Pulse Biosciences, Inc.

Phase NA Completed
30 enrolled 6 charts
Dermatologic

Margins of Excision, Carcinoma, Basal Cell

NCT02159703 2019-11-21

A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
60 enrolled 9 charts
Head & Neck

Margins of Excision, Oropharyngeal Neoplasms

NCT02727894 2019-03-05

CRC

Institute for Clinical and Experimental Medicine

Completed
276 enrolled 9 charts
Gastrointestinal

Margins of Excision, Neoplasm Metastasis, Colorectal Neoplasms

NCT00719264 2017-03-20

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Novartis

Phase 2 Completed
365 enrolled 14 charts
Genitourinary

Margins of Excision, Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡